Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs, as part of a trial co-led by UCL and the Francis Crick Institute.
Read: Evening Standard, More: UCL News